Delivery Order SPE2DB24D1007-SPE2DB25FB5TF
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 mL pen injectors. This firm fixed-price delivery order, valued at $35,744.56, is scheduled for completion by September 24, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was made on a competitive basis with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 ml pen injectors, with a contract ceiling value of $41,933.14. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of September 3, 2025. This delivery order is a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors valued at $7,436.99. This competitively awarded, firm fixed-price contract is classified as a delivery order with an ultimate completion date of August 18, 2025, and involves performance at the contractor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, indicating it was...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors with a ceiling value of $1,143.87. This is a firm fixed-price delivery order with an ultimate completion date of September 9, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a non-competitive delivery order issued under an existing contract vehicle, reflecting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors, with an order ceiling value of $16,756.44. This firm fixed price delivery order is set to be completed by September 29, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a competitive procurement with no set-aside designation, demonstrating AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a $1,525.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors. The award was completed competitively with no set-aside designation and carries an ultimate completion date of September 17, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $14,950.78 to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 mL pen injectors. This competitively awarded, firm fixed-price contract is scheduled for completion by July 24, 2025, with performance taking place at AmerisourceBergen's corporate offices in Conshohocken, Pennsylvania. The contract represents a single delivery order issued under a larger procurement vehicle and carries...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Zepbound (tirzepatide) 2.5 mg/0.5 ml pen injectors in 0.5 ml quantities. This firm fixed-price delivery order, valued at $9,394.59, represents a competitive award with no set-aside designation and is set for completion by August 1, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, serving the federal medical...
- The Defense Logistics Agency awarded a $5,834.04 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 ml pen injectors. This non-competitive, firm fixed-price delivery order is set to be completed by September 5, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pen injectors valued at $3,911.93, with performance through August 25, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under...
- SPE2DB24D1007Indefinite Delivery Contract
- SPE2DB24D1007-SPE2DB25FB5TFDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pen injectors, with a contract ceiling value of $22,877.40. This is a firm fixed-price delivery order with an ultimate completion date of September 29, 2025, and represents a non-competitive award. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999, which runs through December 2026 and serves as a comprehensive pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp is one of the nation's largest pharmaceutical distributors and a critical vendor for federal medical procurement, particularly for Department of Defense and veteran healthcare systems. The company's extensive portfolio of federal contract awards demonstrates its capability to supply a broad spectrum of pharmaceutical products, medical devices, and healthcare commodities across multiple therapeutic domains. The current delivery order for Zepbound, a GLP-1 receptor agonist used for weight management, reflects the company's role in supporting military medical supply needs through competitive, firm fixed-price arrangements that have ranged from minimal values to over $45,000.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $22.9k | 9/26/25 |